Promising Prospects for Vigil Neuroscience Inc. with VG-3927: A Groundbreaking Oral TREM2 Agonist
Analyst Andrew Fein from H.C. Wainwright maintained a Buy rating on Vigil Neuroscience Inc (VIGL – Research Report) and keeping the price ...
Vigil Neuroscience shares rise on positive Alzheimer's trial data
Shares of Vigil Neuroscience , Inc. (NASDAQ:VIGL) climbed 14% after the company reported favorable results from its Phase 1 clinical trial for VG-3927, a potential treatment for Alzheimer's disease ...
Yahoo Finance1mon
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
WATERTOWN, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...
Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that ...
Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment
Vigil Neuroscience, Inc., a clinical-stage biotechnology company listed on the Nasdaq under the symbol VIGL, recently unveiled promising results from its Phase 1 clinical trial for the experimental ...
ETF Daily News27d
Geode Capital Management LLC Purchases 66,712 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)
Vigil Neuroscience Stock Performance Shares of VIGL opened at $1.79 on Friday. Vigil Neuroscience, Inc. has a fifty-two week low of $1.49 and a fifty-two week high of $6.06. The firm has a 50 day ...